Dialysis access treatment trends differ significantly in Japan compared to those in other regions, with physicians choosing short AVF maturation times and strongly favoring hemodialysis over other treatments typically used for ESRD. However, the Japanese market continues to face a number of impediments, including biennial reimbursement cuts and more limited device availability.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for dialysis access treatment products in Japan across a 10-year period.
AVF maturation practices differ in Japan compared to other regions.
What dialysis market device segments are most affected by the short AVF maturation lengths in Japan?
How do procedure volumes in Japan differ from other global markets as a result of these unique treatment practices?
Biennial reimbursement cuts by the MHLW continue to affect the Japanese dialysis access treatment device market.
Which market segments will experience the highest cuts to reimbursement, and why?
In which segments will procedural growth compensate for ASP declines, resulting in market growth?
New technologies like percutaneous AVF catheters are expected to enter the Japan dialysis access treatment device market.
How will the expected approval of percutaneous AVF catheters affect surgical AVF procedure volumes and the use of AVGs?
- Dialysis Access Treatment Devices - Market Insights - Japan
Author(s): Shruthi Narendranath, MSc
Shruthi Narendranath is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in heart valve and periphral vascular device markets. Shruthi holds a Master's degree in Bioinformatics from Cardiff University.